Literature DB >> 3467503

Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis.

J K Dart, R J Buckley, M Monnickendan, J Prasad.   

Abstract

Perennial allergic conjunctivitis (PAC) is a perennial form of seasonal allergic (hay fever) conjunctivitis (SAC). Fourteen subjects with PAC were compared with 25 subjects with SAC. All patients met the same criteria for the diagnosis of a Type 1 ocular allergy. In a study of ophthalmic morbidity at an inner city health centre during the summer months the 3-month period prevalence of PAC was 3.5:10,000. In PAC symptoms are present throughout the year although seasonal exacerbations occurred in 79 per cent. Many similarities were found with SAC. PAC showed the same age range, length of history and symptoms as SAC although SAC was more severe. In both, conjunctival cytology showed eosinophils (PAC 43 per cent; SAC 25 per cent) and total IgE levels were raised in the tears (PAC 100 per cent; SAC 96 per cent) and serum (PAC 79 per cent; SAC 78 per cent). However, PAC differed from SAC in several respects: a history of exacerbation on exposure to house dust (PAC 42 per cent; SAC none) and an association with perennial rhinitis (PAC 75 per cent; SAC 12 per cent) were more common in PAC. The largest response on skin prick testing to a panel of antigens was to house dust mite (Dermatophagoides pteronyssinus) and this was more frequent in PAC (PAC 71 per cent; SAC 4 per cent). Dust mite antigen specific IgE was present in the tears of 78 per cent of cases of PAC, in higher levels than in serum indicating local production of IgE, whereas in SAC there were no detectable levels in any of the tears tested.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3467503

Source DB:  PubMed          Journal:  Trans Ophthalmol Soc U K        ISSN: 0078-5334


  14 in total

Review 1.  Allergic ocular disease. A review of pathophysiology and clinical presentations.

Authors:  L Bielory; P E Goodman; E M Fisher
Journal:  Clin Rev Allergy Immunol       Date:  2001-04       Impact factor: 8.667

Review 2.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

3.  Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries.

Authors:  C G Pinto; A Lafuma; F Fagnani; M J Nuijten; G Berdeaux
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Ocular allergy in pediatric practice.

Authors:  Mark B Abelson; David Granet
Journal:  Curr Allergy Asthma Rep       Date:  2006-07       Impact factor: 4.806

5.  Evaluation of allergic sensitization in Lebanese patients with allergic conjunctivitis.

Authors:  Nicolas Arej; Carla Irani; Youssef Abdelmassih; Elise Slim; Joelle Antoun; Riad Bejjani; Alexandre Schakal; Naji Waked
Journal:  Int Ophthalmol       Date:  2017-08-22       Impact factor: 2.031

Review 6.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

7.  Eosinophil cationic protein in tears in allergic conjunctivitis.

Authors:  P G Montan; M van Hage-Hamsten
Journal:  Br J Ophthalmol       Date:  1996-06       Impact factor: 4.638

Review 8.  Ocular allergies.

Authors:  L Fonacier; J Luchs; I Udell
Journal:  Curr Allergy Asthma Rep       Date:  2001-07       Impact factor: 4.806

Review 9.  Therapeutic options in ocular allergic disease.

Authors:  M Hingorani; S Lightman
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

10.  Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA.

Authors:  D Denis; E Bloch-Michel; P Verin; A Sebastiani; M Tazartes; L Helleboid; A Di Giovanni; M Lecorvec
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.